AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11393872 — intervention group
Group type: EXPERIMENTAL
Intervention: 100-hour rule waiver
Number of subjects: 2
Study 9246276 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide anaesthesia
Number of subjects: 20
Study 9246276 — intervention group
Group type: COMPARATOR
Intervention: Intravenous propofol anaesthesia
Number of subjects: 20
Study 8281587 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular ketorolac 30 mg
Number of subjects: 90
Study 8281587 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal indomethacin 100 mg
Number of subjects: 90
Study 8281587 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 31083195 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia with determination of platelet function
Number of subjects: 156
Study 28441583 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS combined with paroxetine
Number of subjects: 43
Study 28441583 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS combined with paroxetine
Number of subjects: 43
Study 26043354 — intervention group
Group type: EXPERIMENTAL
Intervention: VA bursts present in patients
Number of subjects: 196
Study 26043354 — intervention group
Group type: EXPERIMENTAL
Intervention: VA bursts
Number of subjects: 196
Study 23871109 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational Material group (EDUC)
Number of subjects: 218
Study 23871109 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure group (EXPO)
Number of subjects: 218
Study 23871109 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 218
Study 21914062 — intervention group
Group type: EXPERIMENTAL
Intervention: lamivudine, stavudine and nevirapine
Number of subjects: 389
Study 19783710 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 200 mg/d for 11 days + Warfarin 30 mg on day 5
Number of subjects: 12
Study 19783710 — intervention group
Group type: COMPARATOR
Intervention: Warfarin 30 mg alone on day 1
Number of subjects: 12
Study 17357336 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg 'on-demand'
Number of subjects: 60
Study 17357336 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg daily
Number of subjects: 60
Study 17357336 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg in four-week courses during a relapse
Number of subjects: 60
Study 17357336 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 60
Study 12727707 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA, 2 g/day for 6 weeks
Number of subjects: 36
Study 12727707 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 36
Study 10987586 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 3171
Study 10987586 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 3171
Study 8842054 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol 160mg tablet (Zenith‐Goldline Pharmaceuticals)
Number of subjects: 0
Study 8842054 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol 40mg tablet (Zenith‐Goldline Pharmaceuticals)
Number of subjects: 0
Study 8842054 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol 40mg tablet (80mg dose)
Number of subjects: 0
Study 8842054 — intervention group
Group type: COMPARATOR
Intervention: Corgard 40mg and 160mg tablets (Bristol‐Meyers Squibb)
Number of subjects: 0
Study 1386272 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoladex (goserelin)
Number of subjects: 250
Study 1386272 — intervention group
Group type: COMPARATOR
Intervention: Stilboestrol (3 mg/day)
Number of subjects: 250
Study 6100938 — intervention group
Group type: EXPERIMENTAL
Intervention: High carbohydrate-high fibre diet (HC)
Number of subjects: 15
Study 6100938 — intervention group
Group type: COMPARATOR
Intervention: Reinforced low carbohydrate diet (LC)
Number of subjects: 15
Study 31630485 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic D2 distal gastrectomy
Number of subjects: 0
Study 31630485 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Operation Procedure of Laparoscopic D2 Distal Gastrectomy
Number of subjects: 0
Study 29110384 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin (100 mg)
Number of subjects: 146
Study 29110384 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study 27704313 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg every week (QW) for 12 weeks, then all patients received etanercept 50 mg QW through week 24
Number of subjects: 210
Study 27704313 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study 24660874 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visit intervention (n = 179)
Number of subjects: 360
Study 24660874 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 181)
Number of subjects: 360
Study 22926607 — intervention group
Group type: EXPERIMENTAL
Intervention: oral CYT + O3FA (2 g O3FA twice a day, 1 g CYT twice a day)
Number of subjects: 45
Study 22926607 — intervention group
Group type: EXPERIMENTAL
Intervention: placebo + O3FA (2 g O3FA twice a day)
Number of subjects: 45
Study 22926607 — intervention group
Group type: COMPARATOR
Intervention: placebo + placebo control
Number of subjects: 45
Study 20457540 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist
Number of subjects: 50
Study 20457540 — intervention group
Group type: COMPARATOR
Intervention: GnRH agonist
Number of subjects: 50
Study 18796095 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a (40KD) plus ribavirin (1,000/1,200 mg/day)
Number of subjects: 555
Study 15654292 — intervention group
Group type: EXPERIMENTAL
Intervention: Mecamylamine (15 mg)
Number of subjects: 24
Study 15654292 — intervention group
Group type: EXPERIMENTAL
Intervention: Mecamylamine (7.5 mg)
Number of subjects: 24
Study 15654292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 12144941 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexarelin (2.0 microg/kg, i.v.)
Number of subjects: 24
Study 12144941 — intervention group
Group type: COMPARATOR
Intervention: GHRH (2.0 microg/kg, i.v.)
Number of subjects: 24
Study 12144941 — intervention group
Group type: COMPARATOR
Intervention: Recombinant human GH (10.0 microg/kg, i.v.)
Number of subjects: 24
Study 12144941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 10560994 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone
Number of subjects: 24
Study 10560994 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 8532260 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercially available probe covers
Number of subjects: 360
Study 8532260 — intervention group
Group type: COMPARATOR
Intervention: Condoms
Number of subjects: 360
Study 6687610 — intervention group
Group type: EXPERIMENTAL
Intervention: Type A subjects during socioeconomic exchanges
Number of subjects: 48
Study 6687610 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive interactions
Number of subjects: 48
Study 6687610 — intervention group
Group type: COMPARATOR
Intervention: Type A and Type B subjects
Number of subjects: 48
Study 31288901 — intervention group
Group type: EXPERIMENTAL
Intervention: Ilaprazole
Number of subjects: 330
Study 31288901 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole
Number of subjects: 330
Study 31288901 — intervention group
Group type: EXPERIMENTAL
Intervention: Ilaprazole and Esomeprazole
Number of subjects: 330
Study 30567487 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-pair micro-hole catheter (Contiplex, BRAUN®, 20G - 400 mm)
Number of subjects: 80
Study 30567487 — intervention group
Group type: COMPARATOR
Intervention: End-hole catheter (Silverstim VYGON®, 20G - 500 mm)
Number of subjects: 80
Study 27544861 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipase-catalyzed hydrolysis and esterification reactions using Palatase 20000L
Number of subjects: 0
Study 24962086 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocolized model of antidepressant care
Number of subjects: 150
Study 24962086 — intervention group
Group type: COMPARATOR
Intervention: Model relying on clinical acumen of trained providers
Number of subjects: 150
Study 22564206 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive-behavioral (CB) intervention
Number of subjects: 341
Study 22564206 — intervention group
Group type: COMPARATOR
Intervention: Brochure control
Number of subjects: 341
Study 22564206 — intervention group
Group type: COMPARATOR
Intervention: Bibliotherapy
Number of subjects: 341
Study 19512961 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate extended release (OROS MPH)
Number of subjects: 36
Study 19512961 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 17197465 — intervention group
Group type: EXPERIMENTAL
Intervention: PAx (n=50)
Number of subjects: 100
Study 17197465 — intervention group
Group type: COMPARATOR
Intervention: PLMA (n=50)
Number of subjects: 100
Study 15201697 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazoxide (DZX) 1.5 mg/kg infused intravenously in 5 min followed by a 5‐min washout before cardiopulmonary bypass.
Number of subjects: 40
Study 15201697 — intervention group
Group type: COMPARATOR
Intervention: Control group received placebo infusion.
Number of subjects: 40
Study 11102590 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone implants (800-1200 mg every 3 months)
Number of subjects: 29
Study 11102590 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone implants (800 mg) with finasteride (5alpha-reductase inhibitor)
Number of subjects: 29
Study 11102590 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for comparison with finasteride)
Number of subjects: 29
Study 9519504 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS 60 mg once daily
Number of subjects: 6000
Study 9519504 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6000
Study 8165591 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin (40 mg) administered in the morning and evening for 5 days
Number of subjects: 10
Study 8165591 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 3080694 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyrotropin releasing hormone (TRH) 150 mg IM daily for 2 months
Number of subjects: 30
Study 3080694 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 3051985 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous anisoylated plasminogen streptokinase activator complex (APSAC)
Number of subjects: 240
Study 3051985 — intervention group
Group type: COMPARATOR
Intervention: Intracoronary streptokinase
Number of subjects: 240
Study 3051985 — intervention group
Group type: EXPERIMENTAL
Intervention: Reperfusion (both APSAC and streptokinase)
Number of subjects: 240
Study 31454493 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic Quality Control System (AQCS)
Number of subjects: 659
Study 31454493 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine colonoscopies without AQCS)
Number of subjects: 659
Study 30644815 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized treatment involving percutaneous ablation for risk factors for worsening CKD
Number of subjects: 1000000
Study 30644815 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsy or active surveillance for growth
Number of subjects: 1000000
Study 30644815 — intervention group
Group type: COMPARATOR
Intervention: Routine partial nephrectomy (PN)
Number of subjects: 1000000
Study 30644815 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI guidance for active surveillance
Number of subjects: 1000000
Study 28628707 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure reduction (systolic BP target <140 mm Hg)
Number of subjects: 133
Study 28628707 — intervention group
Group type: COMPARATOR
Intervention: Standard blood pressure reduction (systolic BP target <180 mm Hg)
Number of subjects: 133
Study 26275652 — intervention group
Group type: EXPERIMENTAL
Intervention: Di Huang Yin Zi (DHYZ)
Number of subjects: 100
Study 26275652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 22466697 — intervention group
Group type: EXPERIMENTAL
Intervention: cLkF (Leukocyte filtration of blood cardioplegia)
Number of subjects: 30
Study 22466697 — intervention group
Group type: COMPARATOR
Intervention: Standard cold blood cardioplegia (S-Group)
Number of subjects: 30
Study 21518437 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 145
Study 21518437 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol use
Number of subjects: 145
Study 21518437 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana use
Number of subjects: 145
Study 21518437 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-substance use
Number of subjects: 145
Study 21518437 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance use
Number of subjects: 145
Study 19233936 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial laser therapy (TLT)
Number of subjects: 660
Study 19233936 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 660
Study 16815137 — intervention group
Group type: EXPERIMENTAL
Intervention: 100/50 microg of fluticasone propionate/salmeterol administered through a Diskus inhaler twice daily for 24 weeks
Number of subjects: 88
Study 16815137 — intervention group
Group type: COMPARATOR
Intervention: 250 microg of fluticasone propionate administered through a Diskus inhaler twice daily for 24 weeks
Number of subjects: 88
Study 15178953 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 26
Study 15178953 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 11059698 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory brain stem responses, transient evoked otoacoustic emissions, and distortion product otoacoustic emissions as hearing-screening tools
Number of subjects: 0
Study 11059698 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal test battery including measures of middle-ear function
Number of subjects: 0
Study 11059698 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly reports for monitoring subject enrollment and data integrity checks
Number of subjects: 0
Study 9103129 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone (500 mg oral dose)
Number of subjects: 240
Study 9103129 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 8470978 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac (0.1%) drops
Number of subjects: 53
Study 8470978 — intervention group
Group type: COMPARATOR
Intervention: Placebo drops
Number of subjects: 53
Study 3542826 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic amino acid solution
Number of subjects: 30
Study 3542826 — intervention group
Group type: COMPARATOR
Intervention: Standard fluid therapy
Number of subjects: 30
Study 29703978 — intervention group
Group type: EXPERIMENTAL
Intervention: MR Fingerprinting using slice-interleaved echo-planar imaging (MRF-EPI) with 32 slices acquired in 3:36 minutes
Number of subjects: 0
Study 29703978 — intervention group
Group type: EXPERIMENTAL
Intervention: Phantom scans for validation
Number of subjects: 0
Study 27425563 — intervention group
Group type: EXPERIMENTAL
Intervention: School readiness intervention
Number of subjects: 209
Study 23857798 — intervention group
Group type: EXPERIMENTAL
Intervention: Total 25(OH)D levels
Number of subjects: 2073
Study 23857798 — intervention group
Group type: EXPERIMENTAL
Intervention: Free 25(OH)D levels
Number of subjects: 2073
Study 23857798 — intervention group
Group type: EXPERIMENTAL
Intervention: Total 25(OH)D levels (adjusted for covariates)
Number of subjects: 2073
Study 22402738 — intervention group
Group type: EXPERIMENTAL
Intervention: Better Pittsburgh Sleep Quality Index (PSQI) Global Score
Number of subjects: 245
Study 22402738 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeping >7 h/night
Number of subjects: 245
Study 22402738 — intervention group
Group type: EXPERIMENTAL
Intervention: Worse PSQI Global Score at 6 months
Number of subjects: 245
Study 20142414 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengthening Families Program: For Parents and Youth 10-14 (SFP)
Number of subjects: 381
Study 20142414 — intervention group
Group type: COMPARATOR
Intervention: Family Matters (FM)
Number of subjects: 381
Study 18484981 — intervention group
Group type: EXPERIMENTAL
Intervention: Almotriptan 25 mg
Number of subjects: 866
Study 18484981 — intervention group
Group type: EXPERIMENTAL
Intervention: Almotriptan 6.25 mg
Number of subjects: 866
Study 18484981 — intervention group
Group type: EXPERIMENTAL
Intervention: Almotriptan 12.5 mg
Number of subjects: 866
Study 18484981 — intervention group
Group type: EXPERIMENTAL
Intervention: Almotriptan (all doses)
Number of subjects: 866
Study 18484981 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 866
Study 16404943 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidants - vitamins E and ascorbic acid
Number of subjects: 0
Study 16404943 — intervention group
Group type: COMPARATOR
Intervention: Basic therapy
Number of subjects: 0
Study 12622501 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg disintegrating tablets, administered orally every 12 hours for 3 days
Number of subjects: 96
Study 12622501 — intervention group
Group type: COMPARATOR
Intervention: Placebo, administered orally every 12 hours for 3 days
Number of subjects: 96
Study 12206008 — intervention group
Group type: EXPERIMENTAL
Intervention: Panax notoginseng saponins (PNS) + isovolumic haemodilution (IHD)
Number of subjects: 73
Study 12206008 — intervention group
Group type: EXPERIMENTAL
Intervention: Panax notoginseng saponins (PNS)
Number of subjects: 73
Study 12206008 — intervention group
Group type: EXPERIMENTAL
Intervention: Isovolumic haemodilution (IHD)
Number of subjects: 73
Study 12206008 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 73
Study 9552709 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (3-day regimen)
Number of subjects: 144
Study 9552709 — intervention group
Group type: COMPARATOR
Intervention: Co-amoxiclav (10-day regimen)
Number of subjects: 144
Study 9552709 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 144
Study 8452187 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg oral
Number of subjects: 905
Study 8452187 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone 250 mg intramuscular
Number of subjects: 905
Study 8452187 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin
Number of subjects: 905
Study 8452187 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone
Number of subjects: 905
Study 3334206 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen treatment
Number of subjects: 103
Study 3334206 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 103
Study 29710741 — intervention group
Group type: EXPERIMENTAL
Intervention: Microprocessor-controlled prosthetic knee (i-KNEE)
Number of subjects: 12
Study 29710741 — intervention group
Group type: COMPARATOR
Intervention: Non-microprocessor-controlled prosthetic knee (NMPK)
Number of subjects: 12
Study 27677547 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 281
Study 27677547 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbetocin
Number of subjects: 281
Study 27677547 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 281
Study 25782898 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal gowning/gloving
Number of subjects: 348
Study 25782898 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 348
Study 22929568 — intervention group
Group type: COMPARATOR
Intervention: abciximab infusion with the ClearWay coronary catheter (C)
Number of subjects: 128
Study 22929568 — intervention group
Group type: COMPARATOR
Intervention: standard abciximab infusion (A)
Number of subjects: 128
Study 22929568 — intervention group
Group type: EXPERIMENTAL
Intervention: thrombectomy followed by abciximab infusion with the ClearWay catheter (T+C)
Number of subjects: 128
Study 22929568 — intervention group
Group type: EXPERIMENTAL
Intervention: thrombectomy followed by standard abciximab infusion (T+A)
Number of subjects: 128
Study 20872019 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiport (MP) training
Number of subjects: 40
Study 20872019 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-site access (SSA) training
Number of subjects: 40
Study 20872019 — intervention group
Group type: COMPARATOR
Intervention: MP training on SSA setup after crossover
Number of subjects: 40
Study 20872019 — intervention group
Group type: COMPARATOR
Intervention: SSA training on MP setup after crossover
Number of subjects: 40
Study 18720328 — intervention group
Group type: EXPERIMENTAL
Intervention: Picrotoxin suppositories at 0.001 g three times a week
Number of subjects: 41
Study 18720328 — intervention group
Group type: COMPARATOR
Intervention: Betahistine 3x12 mg
Number of subjects: 41
Study 17361524 — intervention group
Group type: EXPERIMENTAL
Intervention: Chibixiao Recipe (CBX) in combination with minocycline and spironolactone
Number of subjects: 68
Study 17361524 — intervention group
Group type: COMPARATOR
Intervention: Minocycline and spironolactone (control group)
Number of subjects: 68
Study 14585770 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster randomized controlled trials (CRCTs)
Number of subjects: 51
Study 10910241 — intervention group
Group type: EXPERIMENTAL
Intervention: Omentoplasty (Group A)
Number of subjects: 112
Study 10910241 — intervention group
Group type: COMPARATOR
Intervention: No omentoplasty (Group B)
Number of subjects: 112
Study 8910149 — intervention group
Group type: EXPERIMENTAL
Intervention: Albunex (2 to 8 mL injected before and after coronary revascularization)
Number of subjects: 32
Study 8910149 — intervention group
Group type: EXPERIMENTAL
Intervention: Albunex (average total dose of 19 mL +/- 4, 0.25 mL/kg)
Number of subjects: 32
Study 8910149 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Albunex)
Number of subjects: 32
Study 1725447 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine 4 mg p.o. once daily
Number of subjects: 10
Study 1725447 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 6617205 — intervention group
Group type: EXPERIMENTAL
Intervention: i.m. norethisterone enanthate (NET‐e) 200 mg every two months
Number of subjects: 21